Jim Cramer said that he was shocked after Bristol-Myers Squibb announced its lung cancer drug failed in a late-stage study.
The pharmaceutical company reported its cancer drug failed to reach its goals for treating advanced non-small cell lung cancer.
Shares of Merck soared in premarket trading Friday, after the failure of a drug from rival Bristol-Myers Squibb in a late stage study.
Jim Cramer crunched the numbers on two stocks notorious for short-sellers to determine if they are portfolio worthy.
CNBC's Meg Tirrell reports the latest of what Pfizer CEO Ian Read has to say on biotech valuations, the election and more. The “Fast Money Halftime Report” traders and Stephanie Link, TIAA Global Asset Management, weigh in.
The "Fast Money" traders share their first moves for the market open.
The "Fast Money" traders share their final trades of the day, including J.C. Penney, Biogen and more.
Biogen and Ionis Pharmaceuticals soar on a new muscle-disorder drug for babies, CNBC's Meg Tirrell reports. The "Fast Money Halftime Report" traders weigh in.
"Fast Money Halftime Report" traders Jon Najarian and Pete Najarian discuss unusual activity with FireEye and Abbott.
CNBC's Meg Tirrell reports the latest earnings results for AstraZeneca, Bristol-Myers and Celgene.
Thursday looms large as the busiest day of earnings, with pharma, consumer products, big oil, financials and autos reporting.
Bayer surpassed second-quarter earnings expectations and raised its guidance for the year on strong gains in stroke prevention pill Xarelto.
In the face of a potential rate hike by the Federal Reserve, and the presidential conventions, where should you put your money? John Augustine, The Huntington Trust chief investment officer, and Brad McMillan, Commonwealth Financial Network chief investment officer, share their strategies.
People complaining about how risky the stock market is ought to take a look at the so-called safety of today's bond market.
Stephanie Link, TIAA Global Asset Management, and the FMHR traders find value in the market.
CNBC's Dominic Chu discusses where an investor can find protection amidst the market turmoil from the Brexit vote.
Jim Cramer described the energy surrounding a possible Brexit as "hysteria."
Jim Cramer wasn't freaked out by this bold event in the oil patch.
Jim Cramer lays out his game plan for Brexit action next week, and has his eye on black gold to hold the key on when to move.
The "FMHR" traders discuss the biotech and pharmaceuticals trade and give their best bets for stocks.